MX2020010456A - Composiciones que comprenden polimeros reticulados con enlace a cationes. - Google Patents

Composiciones que comprenden polimeros reticulados con enlace a cationes.

Info

Publication number
MX2020010456A
MX2020010456A MX2020010456A MX2020010456A MX2020010456A MX 2020010456 A MX2020010456 A MX 2020010456A MX 2020010456 A MX2020010456 A MX 2020010456A MX 2020010456 A MX2020010456 A MX 2020010456A MX 2020010456 A MX2020010456 A MX 2020010456A
Authority
MX
Mexico
Prior art keywords
compositions
base
crosslinked cation
polymer
equivalents
Prior art date
Application number
MX2020010456A
Other languages
English (en)
Inventor
Linda De Young
Stephen F Carroll
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relypsa Inc filed Critical Relypsa Inc
Publication of MX2020010456A publication Critical patent/MX2020010456A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/755—Polymers containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/04—Acids; Metal salts or ammonium salts thereof
    • C08F220/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/12—Esters of monohydric alcohols or phenols
    • C08F220/16—Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms
    • C08F220/18—Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/102—Esters of polyhydric alcohols or polyhydric phenols of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

En líneas generales, la presente descripción hace referencia a composiciones que comprenden un polímero reticulado con enlaces a cationes que comprenden monómeros que contienen grupos ácido carboxílico y grupos que reducen el pKa que incluyen sustituyentes aceptores de electrones tales como átomos de haluro (por ejemplo, flúor) y una base, en el que el polímero opcionalmente contiene menos de alrededor de 20 000 ppm de cationes diferentes a hidrógeno y en el que la base se encuentra presente en una cantidad suficiente para proveer de alrededor de 0,2 equivalentes a alrededor de 0,95 equivalentes de base por equivalente de grupos ácido carboxílico en el polímero. La presente descripción también hace referencia a métodos para preparar dichas composiciones y a métodos para utilizarlas para tratar diversas enfermedades o trastornos.
MX2020010456A 2012-07-19 2015-01-16 Composiciones que comprenden polimeros reticulados con enlace a cationes. MX2020010456A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261673707P 2012-07-19 2012-07-19

Publications (1)

Publication Number Publication Date
MX2020010456A true MX2020010456A (es) 2020-10-20

Family

ID=49949269

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000810A MX2015000810A (es) 2012-07-19 2013-07-19 Composiciones que comprenden polímeros reticulados con enlace a cationes.
MX2020010456A MX2020010456A (es) 2012-07-19 2015-01-16 Composiciones que comprenden polimeros reticulados con enlace a cationes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015000810A MX2015000810A (es) 2012-07-19 2013-07-19 Composiciones que comprenden polímeros reticulados con enlace a cationes.

Country Status (14)

Country Link
US (1) US20150196585A1 (es)
EP (1) EP2874633A4 (es)
JP (3) JP6232062B2 (es)
KR (1) KR102211670B1 (es)
CN (2) CN105451746A (es)
AU (2) AU2013292350B9 (es)
BR (1) BR112015001230B1 (es)
CA (1) CA2879425A1 (es)
DE (1) DE112013003596T5 (es)
GB (1) GB2519479B (es)
HK (1) HK1203420A1 (es)
IN (1) IN2015DN01369A (es)
MX (2) MX2015000810A (es)
WO (1) WO2014015240A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015244A1 (en) * 2012-07-19 2014-01-23 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers
KR20210005314A (ko) 2012-10-08 2021-01-13 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
US20170022314A1 (en) * 2015-07-24 2017-01-26 Weyerhaeuser Nr Company Grafted crosslinked cellulose
US20170342383A1 (en) 2016-05-27 2017-11-30 Corning Incorporated Lithium disilicate glass-ceramic compositions and methods thereof
EP3717428A1 (en) 2017-11-28 2020-10-07 Corning Incorporated Bioactive borate glass and methods thereof
WO2019108556A1 (en) 2017-11-28 2019-06-06 Corning Incorporated Bioactive glass compositions and dentin hypersensitivity remediation
WO2019108558A1 (en) 2017-11-28 2019-06-06 Corning Incorporated High liquidus viscosity bioactive glass
US10857259B2 (en) 2017-11-28 2020-12-08 Corning Incorporated Chemically strengthened bioactive glass-ceramics
CN108395497B (zh) * 2018-01-22 2021-03-30 中国科学院兰州化学物理研究所 紫外荧光型空间润滑油爬行屏障材料
EP3774714A4 (en) * 2018-04-10 2021-12-22 Arkema, Inc. FUNCTIONAL FLUOROPOLYMERS
WO2020097190A1 (en) * 2018-11-06 2020-05-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of personalized treatment for cardiomyopathy and heart failure and associated diseases by measuring edema and cachexia/sarcopenia
JP2021192000A (ja) 2018-12-28 2021-12-16 フォルシアクラリオン・エレクトロニクス株式会社 経路案内方法、端末装置、経路案内システム及びプログラム
US20210186873A1 (en) * 2019-12-19 2021-06-24 Zaki Yusuf Gel compositions for mitigation of burn injuries, kits containing the gel compositions, and associated methods
US11807700B2 (en) * 2020-08-17 2023-11-07 Saudi Arabian Oil Company Electro-responsive hydrogel for reservoir and downhole application
EP4171582B1 (en) * 2021-09-13 2024-03-13 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymer medicament for treating hyperkalemia and preparation method thereof
CN115570900B (zh) * 2022-09-28 2023-04-07 江西和烁丰新材料有限公司 一种环保型、可长久保存的热敏纸

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524740A (en) * 1976-11-09 1978-09-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions for use in the suppression of gastric reflux
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US8263112B2 (en) * 2000-11-20 2012-09-11 Sorbent Therapeutics, Inc. In vivo use of water absorbent polymers
WO2006073413A1 (en) * 2004-02-20 2006-07-13 The Board Of Trustees Of The University Of Illinois Blood pressure reduction in salt-sensitive
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
JP5000480B2 (ja) * 2004-03-30 2012-08-15 レリプサ， インコーポレイテッド イオンバランス異常の治療の方法および組成物
WO2007067570A1 (en) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
CA2697803A1 (en) * 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
PT2365988E (pt) * 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
CN101385500A (zh) * 2008-10-30 2009-03-18 九三粮油工业集团有限公司 超临界co2萃取大豆粉末磷脂的连续工业化生产工艺
EP2663290A1 (en) * 2011-01-10 2013-11-20 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation- binding polymers and a base, uses thereof

Also Published As

Publication number Publication date
JP6600062B2 (ja) 2019-10-30
GB2519479A (en) 2015-04-22
GB2519479B (en) 2020-05-20
CN110051686A (zh) 2019-07-26
CA2879425A1 (en) 2014-01-23
DE112013003596T5 (de) 2015-04-09
EP2874633A4 (en) 2016-06-29
BR112015001230A2 (pt) 2017-07-04
JP2019034956A (ja) 2019-03-07
WO2014015240A1 (en) 2014-01-23
AU2013292350B2 (en) 2018-08-09
AU2018256550B2 (en) 2020-07-16
AU2018256550A1 (en) 2018-11-22
JP2018024695A (ja) 2018-02-15
EP2874633A1 (en) 2015-05-27
IN2015DN01369A (es) 2015-07-03
CN105451746A (zh) 2016-03-30
KR102211670B1 (ko) 2021-02-02
JP2015528012A (ja) 2015-09-24
MX2015000810A (es) 2015-06-05
AU2013292350A1 (en) 2015-03-05
BR112015001230B1 (pt) 2020-04-22
US20150196585A1 (en) 2015-07-16
JP6232062B2 (ja) 2017-11-15
KR20150058164A (ko) 2015-05-28
JP6423506B2 (ja) 2018-11-14
HK1203420A1 (en) 2015-10-30
AU2013292350B9 (en) 2018-08-23
GB201502802D0 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
AU2018256550A1 (en) Compositions comprising crossed linked cation-binding polymers
PH12019502355A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
SA518391624B1 (ar) Ror- منظمات جاما
WO2015101958A3 (en) Inhibitors of glutaminase
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2015017858A (es) Composicion polimerica solida obtenida por la polimerización de un monómero con contenido de grupo ácido en presencia de un compuesto de polieter.
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
UA117261C2 (uk) Похідні карбоксаміду та їх застосування як медикаментів для лікування гепатиту b
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
SA114350667B1 (ar) بوادئ بلمرة جديدة ثنائية انونية واستخدامها
WO2014096425A3 (en) Prodrugs of monomethyl fumarate (mmf)
MX2016002794A (es) Compuestos antiproliferativos.
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
SG191068A1 (en) New form of administration of enkephalinase inhibitor
PH12016502050A1 (en) Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation
MX2015008314A (es) Fuido de transferencia termica con propiedades de aislamiento electrico.
IN2014CN03509A (es)
MX2016008402A (es) Composiciones acuosas solubles de polimeros de acido poli-itaconico seleccionados.
MX2015008187A (es) Inhibidores de alk deuterados.
MX338697B (es) Composicion de aditivo mejorada para el control y la inhibicion de la polimerizacion de monomeros de vinilo aromaticos, y metodo para la utilizacion de la misma.
MY185543A (en) Polymer composition, its method of preparation, its use and composition comprising it
WO2013177435A3 (en) Hydrophilic, low acid content polymers as stabilizers for water-based emulsions
IN2013MU03773A (es)
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).